{"id":"systemic-doxycycline-and-sham-apdt","safety":{"commonSideEffects":[{"rate":null,"effect":"Photosensitivity"},{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Esophageal irritation"},{"rate":null,"effect":"Vaginal yeast infection"}]},"_chembl":{"chemblId":"CHEMBL2447928","moleculeType":"Small molecule","molecularWeight":"746.90"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Doxycycline works by binding to bacterial ribosomes and inhibiting protein synthesis, while also exhibiting anti-inflammatory effects through inhibition of matrix metalloproteinases and modulation of immune responses. In this trial, it is being tested alongside sham aPDT (a control photodynamic therapy procedure) to evaluate its efficacy in treating periodontal or oral infections. The combination approach may leverage doxycycline's antimicrobial and anti-inflammatory properties in a clinical setting.","oneSentence":"Doxycycline is a broad-spectrum tetracycline antibiotic that inhibits bacterial protein synthesis and possesses anti-inflammatory properties; when combined with sham aPDT (antimicrobial photodynamic therapy), it is being evaluated for its potential antimicrobial and immunomodulatory effects.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:37:03.625Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Periodontal disease (likely indication based on aPDT context)"}]},"trialDetails":[{"nctId":"NCT01595594","phase":"PHASE3","title":"Comparison Between aPDT and Systemic Doxycycline on Non-surgical Periodontal Therapy in Type 2 Diabetics","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2010-03","conditions":"Periodontal Disease, Type 2 Diabetes","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["aPDT Sham"],"phase":"phase_3","status":"active","brandName":"Systemic Doxycycline and Sham aPDT","genericName":"Systemic Doxycycline and Sham aPDT","companyName":"University of Sao Paulo","companyId":"university-of-sao-paulo","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Doxycycline is a broad-spectrum tetracycline antibiotic that inhibits bacterial protein synthesis and possesses anti-inflammatory properties; when combined with sham aPDT (antimicrobial photodynamic therapy), it is being evaluated for its potential antimicrobial and immunomodulatory effects. Used for Periodontal disease (likely indication based on aPDT context).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}